A Gem In Cephalon's Pipeline? Cinquil Offers The Promise Of A Needed Boost
This article was originally published in The Pink Sheet Daily
Executive Summary
Reslizumab, which is in development for eosinophilic esophagitis and severe asthma, is a drug Cephalon investors are keeping a close eye on.